Table 2.
Demographic and baseline comorbidities associated with time to death until Day 60, in the first 246 patients enrolled in the French COVID cohort
| Alive | Dead | Bivariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|
| Missing n (%) | (n = 204) | (n = 42) | HRa (95%CI) | p | aHRb (95% CI) (n = 239–197 alive/42 dead) | p | |
| Demographic and clinical characteristics | |||||||
| Age: median (IQR), year | 0 (0) | 59 [47.75–70] | 74 [65.5–80.75] | 1.06 (1.04–1.09) | <.001 | ||
| Age distribution: no./total (%) | 0 (0) | ||||||
| 15–49 year | 62/204 (30) | 2/42 (5) | 1 | 1 | |||
| 50–64 year | 73/204 (36) | 7/42 (17) | 2.67 (0.55–12.85) | .22 | |||
| 65–80 year | 53/204 (26) | 21/42 (50) | 9.3 (2.18–39.65) | .003 | 5.22 (2.56–10.63) | <.001 | |
| ≥80 year | 16/204 (8) | 12/42 (29) | 18.08 (4.04–80.84) | <.001 | |||
| Male sex: no./total no. (%) | 0 (0) | 108/204 (53) | 31/42 (74) | 2.32 (1.17–4.62) | .02 | 2.97 (1.47–5.99) | 0.002 |
| Ethnic group: no./total no. (%) | 84 (34) | ||||||
| Arab | 9/128 (7) | 5/34 (15) | 2.18 (0.82–5.77) | .12 | |||
| Black | 12/128 (9) | 3/34 (9) | 0.99 (0.3–3.32) | .99 | |||
| Asian | 5/128 (4) | 3/34 (9) | 1.92 (0.57–6.47) | .29 | |||
| White | 96/128 (75) | 22/34 (65) | 1 | ||||
| Healthcare worker: no./total no. (%) | 0 (0) | 21/204 (10) | 1/42 (2) | 0.21 (0.03–1.53) | .12 | ||
| Smoking history: no./total no. (%) | 77 (31) | ||||||
| Never smoked | 95/140 (68) | 18/29 (62) | 1 | ||||
| Former smoker | 34/140 (24) | 9/29 (31) | 1.44 (0.65–3.22) | .37 | |||
| Current smoker | 11/140 (8) | 2/29 (7) | 1.36 (0.31–5.86) | .68 | |||
| Comorbidities: no./total no. (%) | |||||||
| Chronic cardiac disease (not hypertension) | 1 (0.4) | 31/203 (15) | 17/42 (40) | 3.65 (1.97–6.77) | <.001 | ||
| Hypertension | 3 (1) | 48/201 (24) | 25/42 (60) | 3.77 (2.04–6.99) | <.001 | ||
| Chronic pulmonary disease (not asthma) | 0 (0) | 10/204 (5) | 11/42 (26) | 5.33 (2.67–10.62) | <.001 | 4.84 (2.32–10.07) | <.001 |
| Asthma | 0 (0) | 17/204 (8) | 4/42 (10) | 1.17 (0.42–3.28) | .77 | ||
| Chronic kidney disease | 0 (0) | 8/204 (4) | 8/42 (19) | 4.7 (2.17–10.16) | <.001 | ||
| Chronic liver disease | 1 (0.4) | 7/203 (3) | 2/42 (5) | 1.28 (0.31–5.28) | .74 | ||
| Chronic neurological disorder | 0 (0) | 10/204 (5) | 8/42 (19) | 4.11 (1.9–8.89) | <.001 | ||
| Malignant neoplasm | 1 (0.4) | 9/204 (4) | 5/41 (12) | 3.05 (1.19–7.78) | .02 | ||
| Chronic hematologic disease | 0 (0) | 6/204 (3) | 4/42 (10) | 2.49 (0.89–6.99) | .08 | ||
| Obesity | 5 (2) | 30/199 (15) | 14/42 (33) | 2.34 (1.23–4.44) | .009 | 3.32 (1.70–6.52) | <.001 |
| Diabetes | 2 (0.8) | 26/202 (13) | 13/42 (31) | 2.43 (1.26–4.67) | .008 | 1.98 (1.01–3.89) | .048 |
| Rheumatologic disorder | 2 (0.8) | 15/202 (7) | 5/42 (12) | 1.66 (0.65–4.23) | .29 |
Abbreviation: COVID, coronavirus disease.
a
HR: hazard ratios of the association of each factor with mortality.
b
aHR: adjusted hazard ratios of the association with mortality.